# Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Canonical URL: https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-positive-acr-368-phase-2b-endometrial-cancer-clinical-data-with-eu-expansion-to-accelerate-enrollment-initial-acr-2316-clinical-data-and-acr-6840-its-next-ap3-enabled-development-candidate-targeting-cdk11
Ticker: ACRV
Company: Acrivon Therapeutics
Source: Acrivon Therapeutics
Published: 2026-01-08 12:30 EST
Original Source URL: https://ir.acrivon.com
## Summary

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from

## Article Body
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from
## Recent Company News
- 2026-05-21 11:30 EST — [Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit) — Source: Acrivon Therapeutics
- 2026-05-13 20:10 EST — [Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts](https://biopharmsignal.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2026-clinical-catalysts) — Source: Acrivon Therapeutics
- 2026-04-17 20:00 EST — [Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities](https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities) — Source: Acrivon Therapeutics
- 2026-04-15 20:05 EST — [Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Acrivon Therapeutics
- 2026-03-19 11:21 EST — [Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights) — Source: Acrivon Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)